CIK 0001642380 · Non-accelerated filer<br>Smaller reporting company
Insight Molecular Diagnostics Inc.
Sign in to watch- Ticker
- IMDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 271041563
- Phone
- 949-409-7600
- Business address
- 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
- Former names
- OncoCyte Corp, Oncocyte Corp
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Financial Officer bought 97,561 shares at $2.05 ($200,000)
- 4 Open-market buy 10% owner bought 1,077,600 shares at $2.05 ($2,209,080)
- 4 Open-market buy 10% owner bought 5,165,695 shares at $2.05 ($10,589,675)
- 4 Open-market buy 10% owner bought 915 shares at an average $2.01 ($1,839)
- 4 Open-market buy 10% owner bought 4,198 shares at $2.01 ($8,438)
- 4 Open-market buy 10% owner bought 16,055 shares at an average $2.12 ($34,114)
- 4 Open-market buy 10% owner bought 90,219 shares at $2.13 ($192,166)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 12,500 shares at $2.11 ($26,350)
- 4 Open-market buy Chief Financial Officer bought 20,000 shares at $2.29 ($45,800)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Financial Officer bought 33,670 shares at $2.97 ($100,000)
- 4 Open-market buy 10% owner bought 1,315,339 shares at $2.95 ($3,877,619)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 2 of 13 · 257 filings